胆道系统肿瘤(biliary tract cancers,BTC)年发病率各地区差异较大,全球发病率为(1~2)/10万,而中国为(4~5)/10万,5年存活率<5%,总体预后极差[1]。手术、放疗和系统化疗是BTC治疗的主要手段。只有10%的病人确诊时有机会手术。局部进展、转移性或复发病人只能接受化疗。目前的方案主要以吉西他滨为主,可以联合氟脲嘧啶类或铂类[2],但治疗效果均不佳。肿瘤免疫和免疫治疗的 The annual incidence of biliary tract cancers (BTC) varies greatly from region to region, with a global incidence of (1-2) / 100,000 while in China (4-5) / 100,000, a 5-year survival rate of <5 %, Poor overall prognosis [1]. Surgery, radiotherapy and systemic chemotherapy are the main means of BTC treatment. Only 10% of patients have a chance of surgery when diagnosed. Local progression, metastatic or recurrent patients only receive chemotherapy. The current program is mainly gemcitabine-based combination of fluorouracil or platinum [2], but the treatment effect is not good. Tumor immunity and immunotherapy